Abstract Gastric cancer is a signiWcant cause of morbidity and mortality worldwide. Surgical resection remains the primary curative treatment for gastric adenocarcinoma, but the poor (15-35%) survival rate at 5 years has prompted many studies for new therapeutic strategies, such as speciWc immunotherapy. The aim of this study was to analyze the functional properties of the T cell response to diVerent antigen peptides related to gastric cancer in patients with gastric adenocarcinoma. To this purpose, we have cloned and characterized tumor-inWltrating T cells (TILs) isolated from the neoplastic gastric tissue samples. A T cell response speciWc to diVerent peptides of gastric cancer antigens tested was documented in 17 out of 20 patients, selected for their HLA-A02 and/or -A24 alleles. Most of the cancer peptidespeciWc TILs expressed a Th1/Tc1 proWle and cytotoxic activity against target cells. The eVector functions of cancer peptide-speciWc T cells obtained from the peripheral blood of the same patients were also studied. The majority of peripheral blood peptide-speciWc T cells also expressed the Th1/Tc1 functional proWle. In conclusion, in most of the patients with gastric adenocarcinoma, a speciWc type-1 T cell response to gastric cancer antigens was detectable and would have the potential of hamper tumor cell growth. However, in order to get tumor cell killing in vivo, the activity and the number of cancer peptide-speciWc Th1/Tc1 cells probably need to be enhanced by vaccination with the appropriate cancer antigenic peptides or by injection of the autologus tumor peptide-speciWc T cells expanded in vitro.
Introduction
Gastric cancer is a signiWcant cause of morbidity and mortality worldwide [11] . It remains the second most frequently diagnosed cancer in the world, accounting for 10% of all new cancer diagnoses. It has been estimated that there will be more than 870,000 deaths for this disease in the year 2010, accounting for approximately 12% of all cancer deaths [20] .
Gastric cancer is the end result of the interplay of many risk factors as well as of protective factors. Genetic and environmental elements are likely to play a role in the etiology of the disease. Several factors are suspected to play a role in gastric carcinogenesis, including the eVects of diet, e.g., the low intake of animal fats and proteins is associated with a decreased risk of cancer development [25] . Infectious agents, particularly Helicobacter pylori, may also play a role [14, 42] . H. pylori-mediated events, such as production of reactive oxygen radicals, activation of growth factors and cytokines, and alterations of signal transduction processes are potential risk factors for gastric adenocarcinoma [35, 41] . Hereditary elements increase as well the risk of gastric cancer and this malignancy is part of a number of familial cancer syndromes, the most celebrated case being Napoleon Bonaparte [24] . Also the polymorphism of Interleukin(IL)-1 and IL-8 genes has been associated with increased risk of gastric cancer [10, 40] .
Surgical tumor resection remains the primary curative treatment for gastric cancer. Nevertheless, the overall 5-year survival rate remains poor, ranging between 15 and 35%. Among patients who relapse after curative surgery, the 87% have locoregional recurrences [43] .
These facts have prompted many studies addressing surgical issues, as well as exploring the role of adjuvant and neoadjuvant treatments, such as perioperative chemotherapy, which associate with a 5-year overall survival beneWt of 13% for stage II or III operable gastric cancer patients [1] . Worldwide, despite the improvements, estimated cure rates for patients with stages IIIA and IIIB remain poor [23] . These data highlight the urgent need of new therapeutic strategies to combat gastric cancer, such as epithelial growth factor receptor (EGFR) inhibitors [49] , anti-angiogenetic agents [46] , apoptosis promoters [39] and speciWc immunotherapy [9] .
The Wght against gastric cancer has adopted several approaches to exploit the cancer-speciWc immune response [9] , such as patient vaccination with dendritic cells pulsed with HER-2/neu-derived peptides [21] and vaccination by injection of peptides of tumor-associated antigens [44, 45] . In various studies of gastric cancer immunotherapy, there were positive eVects for only a few patients. The disparities registered in cancer immunotherapy trials might be due to a diVerent degree or type of immune response to the tumor antigens in individual patients. The functional properties of the gastric cancer antigen-speciWc T cells have not yet fully elucidated.
The aim of this study was to characterize the eVector functions of the gastric cancer-associated antigen (GCAA) peptide-speciWc T cells, isolated from either the gastric cancer tissue or the peripheral blood of patients with gastric adenocarcinoma.
Materials and methods

Patients
Twenty patients (mean age 68 years) were enrolled in the study. Fully informed consent and approval of the local Ethical Committee were obtained. The characteristics of the patients are summarized in Table 1 . Patients were selected on the basis of their HLA-A02 and/or HLA-A24 alleles. In all patients the diagnosis of gastric adenocarcinoma was conWrmed at pathology: 8 cases had the diVuse type cancer, and 12 had the intestinal type. Patients underwent surgical resection of the primary lesion and did not receive chemotherapy. Gastric biopsies were obtained by endoscopy from 15 patients with chronic gastritis (mean age 65 years) and HLA-A02 and/or HLA-A24 alleles (disease controls). Patients with the evidence of serious illness, immunosuppression, autoimmune or infectious diseases were excluded.
Reagents
Recombinant human IL-2 was a kind gift from Eurocetus (Milan, Italy). PHA (M form) was purchased from Gibco Laboratories (Grand Island, USA), ionomycin and phorbol 12-myristate 13-acetate (PMA) from Sigma (St. Louis, USA). Anti-CD3, anti-CD4, anti-CD8, anti-IFN-, anti-IL-4, anti-CD28 and anti-CD49d monoclonal antibodies (mAbs) were purchased from BD Biosciences (San Jose, USA); the mAbs anti-HLA-DR and anti-HLA-A-B-C were purchased from Immunotech (Beckman Coulter, Marseille, France). The peptides of gastric cancer-associated antigens (GCAA) used in the present study were prepared by Multiple Peptide System (San Diego, USA). The sequences of the GCAA peptides are reported in Table 2 . All these peptides have proven the ability to induce HLA-A02-or HLA-A24-restricted and tumor-speciWc cytotoxic lymphocyte activity in the PBMCs of gastric cancer patients [27, 47, 51] .
Generation of T cell clones from TILs of the neoplastic gastric tissue
Surgical specimens of gastric cancer tissue or endoscopic biopsy samples from the gastric mucosa of control patients with chronic gastritis were cultured for 7 days in RPMI 1640 medium supplemented with IL-2 (50 U/ml) in order to expand in vivo-activated TILs. Specimens were then disrupted, and single T cell blast was cloned under limiting dilution, as described [4] . BrieXy, single T cell blasts were seeded in microwells (0.3 cells/well) in the presence of 2 £ 10 5 irradiated (5,000 rad) PBMC, PHA (0.5% vol/vol), and IL-2 (50 U/ml). At weekly intervals, 2 £ 10 5 irradiated PBMC and IL-2 were added to each microculture to maintain the expansion of growing clones. T cell clones were screened for responsiveness to GCAA peptides by measuring [ 3 H]thymidine (Amersham Pharmacia Biotech, Uppsala, Sweden) uptake after 60-h co-culture with irradiated autologous mononuclear cells in the presence of medium or GCAA peptides (10 g/ml). The mitogenic index (MI) was calculated as the ratio between mean values of cpm obtained in stimulated cultures and those obtained in the presence of medium alone. A MI¸5 was considered as positive.
Analysis of TCR Vß chain repertoire of GCAA peptide-speciWc T cell clones
The repertoire of the TCR Vß chain of GCAA peptide-speciWc T cell clones was analyzed with a panel of 24 mAbs Detection of GCAA peptide-speciWc T cells in the peripheral blood of patients with gastric cancer To test the presence of GCAA peptide-speciWc T cells in the peripheral blood of patients with gastric adenocarcinoma, PBMCs obtained by density gradient centrifugation on Ficoll-Hypaque were resuspended in medium with 3% human serum. PBMCs (3 £ 10 5 ) were cultured for 96 h in the presence of medium alone or single GCAA peptides (10 g/ml). At 16 h before harvesting, 0.5 Ci/well [ 3 H]thymidine was added, and the radionuclide uptake was measured by a -counter. A MI >5 was considered as positive.
CytoXuorimetric analysis of T cell surface markers and characterization of the cytokine proWle of GCAA peptide-speciWc T cell clones Cell surface marker analysis of T cells was carried out by two-or three-color Xow cytometry using Xuorochromeconjugated anti-CD3, anti-CD4, anti-CD8. The cells were analyzed on a BD FACScan cytoXuorimeter using the Diva software (BD Biosciences, San Jose, USA). A total of 10 4 events for each sample were acquired.
To induce the cytokine production by GCAA peptidespeciWc T cell clones, 10 6 T cell blasts of each clone were co-cultured for 48 h in 1 ml medium with 5 £ 10 5 irradiated autologous PBMCs as antigen presentig cells (APC) with or without single GCAA peptides (10 g/ml).
To elicit cytokine production by non-GCAA-speciWc T cell clones, T cell blasts were resuspended at 10 6 /ml medium and cultured for 36 h in the presence of PMA (10 ng/ml) plus ionomycin (200 ng/ml). Cell-free supernatants were collected and assayed in duplicate for IFN-and IL-4 content by commercial ELISA assays (Bio-Source International, Camarillo). Supernatants showing IFN-or IL-4 levels 5 SD over the mean levels in control supernatants derived from irradiated APC alone were regarded as positive. CD4 + and CD8 + T cell clones able to produce IFN-, but not IL-4, were categorized as Th1 or Tc1, respectively, whereas clones able to produce both IL-4 and IFN-, as Th0 or Tc0, respectively.
Preparation of Epstein-Barr virus transformed (EBV-B) cells
B cell-enriched suspensions were prepared by a double-step rosetting with neuraminidase-treated sheep erythrocytes, as described elsewhere [6] . Peripheral blood B cell-enriched suspensions usually consisted of 68-87% B cells, 9-21% monocytes, and ·1% T cells. They will be referred to as B cells. To obtain EBV-transformed lymphoblastoid B cell lines, B cells were incubated for 48 h with supernatant of the EBV-producing marmoset cell line B95.8 and subsequently expanded in complete medium supplemented with 15% FCS.
Perforin-mediated cytotoxicity and Fas-Fas Ligand(L)-mediated proapoptotic activity
Perforin-mediated cytolytic activity of T cell clones was assessed as reported [5] . T cell blasts of GCAA peptide-speciWc clones were incubated at eVector to target ratios of 10, 5, and 2.5-1 with 51 Cr-labeled autologous EBV-B cells preincubated with peptide (10 g/ml). After centrifugation, microplates were incubated for 8 h at 37°C, and 0.1 ml supernatant was removed from each microculture for measurement of 51 Cr release. The ability of GCAA peptide-speciWc T cell clones to induce Fas-FasL-mediated apoptosis was assessed using Fas + Jurkat cells as target [50] . T cell blasts from each clone were co-cultured with 51 Cr-labeled Jurkat cells at eVector to target ratios of 10, 5, and 2.5-1 for 18 h in the presence of PMA (10 ng/ml) and ionomycin (1 mmol/l), as reported [4] . To block Fas-FasL interaction, the anti-Fas antagonistic monoclonal antibody M3 (Amgen, Thousand Oaks, USA) was used at a 5 g/ml Wnal concentration in a 30-min pretreatment of 51 Cr-labeled Jurkat cells, as reported [3] .
Generation of GCAA peptide-speciWc T cell lines
Peptide-speciWc T cell lines were generated as described [7] . BrieXy, 10 6 PBMC in 2 ml RPMI 1640 medium supplemented with 2 mM L-glutamine, 2 £ 10 ¡5 M 2-ME, and 5% human serum (complete medium) were stimulated with single GCAA peptides (10 g/ml) in 24-well Xat-bottom plates for 5 days. Human IL-2 (30 U/ml) was then added, and cultures were continued for 7 days. Viable T cell blasts were resuspended in complete medium and tested for their intracytoplasmatic cytokine expression.
CytoXuorometric analysis of the intracytoplasmic cytokine production of the GCAA peptide-speciWc T cell lines CytoXuorometric analysis of intracytoplasmic IFN-and IL-4 synthesis in GCAA peptide-speciWc T cell lines was performed after 10 days of culture. BrieXy, after washing with PBS, 1 £ 10 6 T cell blasts were stimulated with single peptides (10 g/ml) plus anti-human CD28 (1 g/ml) and anti-human CD49d (1 g/ml) for 6 h, being the last two mAbs added in the presence of brefeldin A (5 g/ml). After incubation, cells were washed twice with PBS, pH 7.2, Wxed 15 min with formaldehyde (2% in PBS, pH 7.2), washed twice with 0.5% BSA in PBS, pH 7.2, permeabilized with PBS, pH 7.2, containing 0.5% BSA and 0.5% saponin, and then incubated with the speciWc mAbs. Cells were analyzed on a FACScan cytoXuorometer using the Diva software. The area of positivity was determined using an isotype-matched mAb. In all cytoXuorometric analysis, a total of 10 4 events, gated as CD3 + CD4 + or CD3 + CD8 + cells, for each sample, were acquired.
Results
GCAA peptide-speciWc T cells inWltrate the neoplastic tissue of patients with gastric adenocarcinoma
T cell clones derived from the TILs of gastric cancer patients were assayed for proliferation in response to each of the GCAA peptides reported in Table 2 . Among the 437 CD4 + TIL-derived T cell clones, 65 (15%) ( Table 1) proliferated to diVerent GCAA peptides. Of the 65 peptide-speciWc CD4 + T cell clones, 30 were activated by peptides restricted by HLA-A24, whereas the other 35 recognized their target peptide in the context of HLA-A02 (Table 1 ; Fig. 1 ). Among the 316 CD8 + T cell clones generated from the TILs of gastric cancer (Table 1) , 59 (18%) proliferated to GCAA peptides: namely, 29 CD8
+ clones responded to peptides restricted by HLA-A24 and 30 to peptides restricted by HLA-A02 (Table 1 ; Fig. 1 ). Under the same experimental conditions, none of the 282 CD4 + and none of the 120 CD8 + T cell clones obtained from endoscopic biopsies of the gastric mucosa of patients with chronic gastritis showed signiWcant proliferation to any GCAA peptide ( Table 1) . As shown in Fig. 1 , in the series of TIL-derived clones, we found CD4 + and/or CD8 + clones reactive to one or more peptides of the panel of GCAA peptides used in this study (Table 3) , those of antigens SART and lck having higher chance to be recognized by the clonal progenies of TILs from our patients. However, in three patients (1.BB, 7.CS, and 16.MG) (15%) we were unable to isolate any T cell clone speciWc for any of the GCAA peptides used in this study. Evidence for clonality of GCAA peptide-speciWc T cell clones was provided by the cytoXuorimetric patterns of single TCR-Vß expression shown by those clones. Each T cell clone was stained by only one of the TCR-Vß chainspeciWc monoclonal antibodies, showing a single peak of Xuorescence intensity (Fig. 2) .
To assess whether the responses of CD4 + T cell clones were HLA class I-or class II-restricted, cell proliferation tests with GCAA peptides were performed in the presence of autologous mononuclear cells and anti-HLA class I or anti-HLA class II blocking mAbs (10 g/ml). On the basis of the results obtained (Table 4) , it is possible to conclude that some TIL-derived CD4 + T cell clones (38 of 65, 58%) showed an HLA class I-restricted response to GCAA peptides, whereas the response of the rest of CD4 + clones (27 of 65, 42%) was HLA class II-restricted. The number of peptide-speciWc CD4 + T cell clones that exhibited proliferation in a MHC class I manner is very restricted (one or two per patient). As expected, all the CD8 + GCAA peptide-speciWc T cell clones showed an HLA class I-restricted response.
Th1/Tc1 eVector functions of TIL-derived T cell clones speciWc for GCAA peptides
The cytokine proWle induced in peptide-speciWc TILderived T cell clones by stimulation with the appropriate GCAA peptide in the presence of irradiated autologous APC was then assessed. Upon stimulation with the speciWc peptide, the majority of peptide-reactive CD4 + and/or CD8 + clones produced IFN-, but not Th2 cytokines, expressing thus the Th1/Tc1 proWle, whereas 17% of CD4 + and 25% of CD8 + clones expressed a Th0 or Tc0 proWle, respectively, with production of both IFN-and IL-4 (Fig. 3) .
Since most of antigen-activated Th1 and Th0 clones express perforin-mediated cytotoxicity against autologous antigen-presenting APC (e.g., GCAA peptidepulsed B cells) [3] , we assessed the cytolytic potential of peptide-speciWc T cell clones using GCAA peptide-pulsed 51 Cr-labeled autologous EBV-B cells as targets. At an eVector to target ratio of 10:1, all 50 CD4 + Th1 and 11 out of the 15 Th0 CD4 + clones lysed GCAA peptide-presenting autologous EBV-B cells (Fig. 4) . Likewise, all the 59 CD8 + (44 Tc1 and 15 Tc0) T cell clones lysed GCAA peptidepresenting autologous EBV-B cells, at an eVector to target ratio of 10:1 or lower.
Because activated eVector T cells can also kill their targets by inducing apoptosis through Fas-FasL interaction [50] , the ability of activated peptide-speciWc T cell clones to induce 51 Cr release by Fas + Jurkat cells undergoing apoptosis was evaluated. Upon mitogen activation, 50 of 65 CD4 + (77%) and 50 (85%) out of 59 CD8 + clones were able to induce apoptosis in target cells (Fig. 5) . The role of FasFasL interaction in the 51 Cr release was conWrmed by its inhibition (range 39.6-59.8%) using a blocking anti-Fas antibody (data not shown). and Tc1 and Tc0 CD8 + T cell clones were stimulated with the appropriate peptides (10 g/ml), and IFN-and/or IL-4 production was measured in culture supernatants by speciWc ELISA assays. In supernatants of control cultures stimulated with medium alone, levels of IFN-and IL-4 were consistently <0.05 and <0.01 ng/ml. Dotted lines represent 3 SD over the mean levels of IFN-and IL-4 measured in control cultures Fig. 4 Cancer antigen peptide-induced cytotoxicity of TIL-derived peptide-speciWc CD4 + and CD8 + T cells clones. To assess their perforin-mediated cytotoxicity, T cell clones were cocultured with 51 Cr-labeled autologous EBV-B cells pulsed with the appropriate GCAA peptides. Results represent mean values of percent speciWc 51 Cr release at an eVector to target ratio of 10-1 in triplicate microcultures. The dotted line represents 3 SD over the mean 51 Cr release in cultures with 51 Cr-labeled autologous EBV-B cells pulsed with medium alone + PBMCs recognized only HLA-A24 restricted GCAA peptides. The PBMCs from the remaining six patients with gastric adenocarcinoma or from the 15 chronic gastritis patients did not proliferate to any of the GCAA peptides tested.
Predominant Th1/Tc1 proWle of GCAA peptide-speciWc T cell lines derived from PBMCs of patients with gastric cancer Upon 5-day stimulation of patient PBMC with single GCAA peptides, peptide-speciWc T cell lines were expanded with IL-2 for additional 7 days. Peptide-speciWc T cell lines could be obtained from 16 out of the 20 patients studied, whereas no viable T cell line was derived from four of the six patients whose PBMCs did not proliferate to any of the tumor peptides. Incidentally, three of those four patients (1.BB, 7.CS and 16.MG) were the same in which we failed to derive and expand any tumor antigen-speciWc T cell clone. On day 10, viable T cell blasts of the peptidespeciWc T cell lines were resuspended in complete medium and tested for their intracytoplasmatic cytokine expression. After stimulation with the appropriate HLA-A-restricted peptide in the presence of costimulatory molecules (anti-CD28 and anti-CD49d), all T cell lines included a remarkable proportion of peptide-speciWc CD4 + and CD8 + Th1 (average 11%) and Tc1 (average 15%) cells able to produce intracytoplasmic IFN-, but only a few Th0 and Tc0 cells expressing both IFN-and IL-4 (Table 5) . In other words, the data from the peripheral blood conWrmed the Th1/Tc1 predominance of the GCAA peptide-speciWc T cells derived from TILs of the gastric neoplastic tissues. It is interesting that in almost all patients the peptides that induced the production of IFN-in PBMC were the same that stimulated the proliferation of the GCAA peptidespeciWc T cell clones isolated from the neoplastic tissues.
Discussion
In this study, the T cell response speciWc to gastric cancerassociated antigen (GCAA) peptides in 20 patients with gastric adenocarcinoma was analyzed. The use of a series of GCAA peptides allowed us to demonstrate the presence among the gastric tumor-inWltrating lymphocytes of T cells speciWc for GCAA peptides presented and restricted by HLA-A02 and/or HLA-A24 histocompatibility molecules. In view of the small number of TILs that can be recovered, the study took advantage of a high eYciency cloning procedure allowing the clonal expansion of virtually every single T cell [30] . The analysis of the clonal progeny of TILs isolated from the neoplastic tissue showed a large predominancy of both CD4 + and CD8 + T cell clones able to secrete IFN-, whereas the concomitant production of IFN-and IL-4 was limited to only a few clones. Therefore, the majority of gastric cancer TILs speciWc for GCAA peptides expressed the Th1 or Tc1 cytokine proWle, whereas a much smaller proportion of GCAA peptide-speciWc TILs expressed the Th0 or Tc0 proWle, according to their CD4 or CD8 phenotype, respectively.
A reasonable question is whether this pattern does indeed reXect the real functional behavior of gastric cancer TILs in vivo, or it is the result of in vitro artifacts due to culture in IL-2 and cloning procedure. In previous studies, however, using the very same culture and cloning protocol, T cell clones with predominant Th0 proWle were obtained from the gastric mucosa of patients with chronic gastritis [2] and T cell clones polarized into the Th2 proWle were obtained from the bronchial inWltrates of patients with allergic asthma [8] .
Similar proportions of GCAA peptide-speciWc T cell clones were derived from CD8 + (18%) and CD4 + (15%) [5, 12, 37, 48] . Accordingly, in our present studies we have found that a restricted number (one or two per patient) of speciWc CD4 + T cell clones showed an HLA class I-restricted response to GCAA peptides.
The series of peptide-speciWc TIL-derived T cell clones included clones with diVerent speciWcity for HLA-A02 and/ or HLA-A24 restricted tumor antigen peptides. Although the repertoire of peptide speciWcity of TIL-derived T cell clones was wide (Table 3) , including almost each of the diVerent GCAA peptides tested, those speciWc for peptides belonging to SART3 and lck cancer antigens were the majority, being 24 and 32, respectively. For this aspect, our results are in agrement with the data of previous studies, which reported that the host immune response to gastric cancer frequently target SART and lck tumor-associatedantigens [16, 26, 33, 36] .
The presence in the context of gastric cancer of cancer antigen peptide-speciWc TILs suitable for detection and clonal expansion is not a rule, because in up to 15% of our gastric cancer patients it was not possible to isolate and to expand any GCAA peptide-speciWc T cell clone, in spite of their appropriate HLA-A02 and/or HLA-A24 alleles. The simplest explanation for this failure is that a speciWc T cell response against the tumor antigens was missing or extremely poor in such patients because they were made somehow 'tolerant' to their gastric cancer antigens. However, the mechanisms responsible for such an anergic or tolerant state to gastric cancer remain unclear.
Using GCAA peptide-pulsed 51 Cr-labeled autologous EBV-B cells as targets, we could demonstrate that all the CD8 + and 94% of CD4 + peptide-speciWc TIL-derived clones were equipped with the cytotoxic machinery required for the lysis of target cells. Furthermore, upon mitogen activation, 81% of the GCAA peptide-speciWc TIL clones were able to induce apoptosis in target cells by FasFasL interaction.
Taken together these results conWrm that the TILderived clones speciWc for GCAA peptides are able to express a cancer peptide-speciWc cytotoxic activity, which may represent an important pre-requisite for eVective gastric cancer immunotherapy [29, 44] .
In the second part of the study, we analyzed whether T cells obtained from the peripheral blood of patients with gastric adenocarcinoma might have similar eVector functions to those of TILs obtained from the gastric neoplastic lesions of the same patients. The presence of T cells speciWc for GCAA peptides in the peripheral blood has been documented in 14 (70%) out of the 20 patients with gastric cancer. For the six gastric cancer patients in which GCAA peptide-speciWc T cells were not detectable in the peripheral blood, we suspect that their number was too small and below the sensitivity of the methods used or that virtually all the GCAA peptide-speciWc T cells homed into the neoplastic tissue, without consistent recirculation to the periphery. Of interest is the observation that among the six patients apparently lacking peptide-speciWc T cells in their peripheral blood, there were three patients (1.BB, 7.CS and 16.MG) in which we were unable to isolate and expand TIL-derived T cell clones speciWc for GCAA peptides, suggesting that a number of gastric cancer patients can indeed lack a cancer-speciWc T cell response, as already suggested in recent studies [18, 31] .
Finally, we assessed the cytokine proWle of GCAA peptide-speciWc T cells isolated from the peripheral blood of gastric cancer patients, and for each patient single GCAA peptides were used to induce speciWc T cell lines which have been subsequently studied by intracytoplasmic cytoXuorometric analysis. In most of the patients (16 out of 20) we obtained GCAA peptide-speciWc T cell lines that, upon stimulation with the speciWc peptide, included a quite high number of T cells expressing intracytoplasmic IFN-, whereas T cells positive for intracytoplasmic IL-4 were very few or missing. These data support the notion that the majority of both gastric-derived and circulating T cells speciWc for gastric cancer antigens tend to express a Th1 or Tc1 proWle. In addition, the production of cytokines was induced by the identical GCAA peptides that were able to evoke a speciWc T cell response at intra-tumor level of the same patients.
Since in none of the three patients (1.BB, 7.CS and 16.MG) apparently lacking GCAA peptide-speciWc TILs, in vitro stimulation with cancer peptides failed to generate GCAA peptide-speciWc T cell lines, we favor the hypothesis that those patients were actually unable to raise a T cell immune response against their gastric adenocarcinoma. On the other hand, the pre-vaccination screening proposed by some studies [44] before generating peptides to be used for anti-tumor vaccination can explain some of the negative responses that are not caused by a lack of immune response to cancer, but would be due to a small number of speciWc T cells circulating in the body.
According to our in vitro data, almost all the TILderived T cell clones isolated from gastric tumors showed a strong cytotoxic activity, which, however, was not eVective in vivo to block the growth and the progression of their gastric cancer. A possible explanation of this discrepancy is that the in vivo conditions of activation of cancer antigenspeciWc T cells are quite diVerent from those achieved in vitro, in which hampering of T cell response by regulatory T cells, immunosuppressive cytokines or other suppressive mechanisms are missing. Indeed, gastric cancer cells could inactivate the T cell cytotoxic activity through various mechanisms, such as tumor escape, production of blocking factors of the T cell response [22, 32] or through inappropriate recruitment of regulatory T cells [15] . In the case of a negative direct action of the tumor cells on the T cell response, also immunotherapeutic vaccination would have poor chance to be eVective [9] .
This study provided evidence that the majority of patients with gastric adenocarcinoma host in their neoplastic tissue a T cell response speciWc for MHC-class I restricted peptides belonging to tumor-associated antigens. In agreement with previous studies [28] that correlated the peptide-speciWc IgG levels in postvaccination sera with prolonged survival in advanced cancer patients vaccinated with peptides, we have demonstrated that a T cell GCAA peptide-speciWc response is also detectable in the peripheral blood, suggesting that TIL can recirculate in the periphery. There are however some exceptions, i.e., patients who apparently lack a T cell response to neoplastic antigens in their peripheral blood, in spite of the presence of cancer antigen-reactive T cells within the cancer tissue. Finally, there are a few patients who apparently lack cancer antigenreactive T cells in either the tumor or the periphery.
Even though in most of the patients with gastric adenocarcinoma, a speciWc Th1/Tc1 cytotoxic T cell response to cancer antigen peptides was detectable, their capacity of hampering tumor cell growth was actually poor and ineVective in vivo. However, if the cancer peptide-speciWc Th1/ Tc1 response would be enhanced by vaccination with the appropriate cancer peptides or by injection of autologous GCAA peptide-speciWc T cells expanded in vitro, tumor cell killing in vivo might become reasonably achievable.
